Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503906 · ClinicalTrials.gov registry record · Phase 2
Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00503906 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 30 participants.
The verdict
NCT00503906, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease, 6 or more months after primary treatment.
Interventions
- DRUG Gemcitabine
- DRUG Abraxane
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503906
The ClinicalTrials.gov registry entry for NCT00503906 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00503906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503906 about?
NCT00503906 is a clinical study titled "Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer". The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease,...
What is the current status of trial NCT00503906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00503906?
The interventions under investigation include: Gemcitabine (DRUG), Abraxane (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00503906?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.